Findings

What do systematic reviews say?

306 questions · 324 findings · 26 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 59 · 18.2%GRADE not reported 30 · 9.3%Very low 91 · 28.1%Low 62 · 19.1%Moderate 78 · 24.1%High 4 · 1.2%

Paliperidone palmitate vs risperidone long‐acting injection

Cost ‐ not measured · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Paliperidone palmitate for schizophrenia 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Paliperidone palmitate vs risperidone long‐acting injection

Health related quality of life ‐ not measured · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Paliperidone palmitate for schizophrenia 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Paliperidone palmitate vs risperidone long‐acting injection

Leaving the study early · patients with schizophrenia

Paliperidone palmitate showed no clear difference in leaving the study early ‐ any reason Reported by trial author compared with risperidone long‐acting injection (high certainty).

1 finding from 1 review

Paliperidone palmitate for schizophrenia 2012 · Cochrane Headline outcomes only
RR 1.12 [1, 1.25]
2 studies · 1969 participants
High

Paliperidone palmitate vs risperidone long‐acting injection

Leaving the study early ‐ lack of efficacy Reported by trial author · patients with schizophrenia

Paliperidone palmitate probably leads to higher leaving the study early ‐ lack of efficacy Reported by trial author compared with risperidone long‐acting injection (moderate certainty).

1 finding from 1 review

Paliperidone palmitate for schizophrenia 2012 · Cochrane Headline outcomes only
RR 1.35 [1.06, 1.71]
2 studies · 1969 participants
Moderate

ZOTEPINE vs RISPERIDONE

Behaviour: No clinically important response (as defined by the original studies) · patients with schizophrenia

1 finding from 1 review

Zotepine versus other atypical antipsychotics for schizophrenia 2010 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

ZOTEPINE vs RISPERIDONE

Global state: No clinically important response (as defined by the original studies) · patients with schizophrenia

1 finding from 1 review

Zotepine versus other atypical antipsychotics for schizophrenia 2010 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

ULTRA LOW DOSE (<2 mg/day) vs ANY DOSE ‐ short term

Leaving the study early · patients with schizophrenia

ULTRA LOW DOSE (<2 mg/day) showed no clear difference in leaving the study early: Any reason ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).

2 findings from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.3 [0.93, 1.83]
2 studies · 461 participants
Moderate
Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.04 [0.76, 1.43]
1 study · 459 participants
Moderate

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia

LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to higher leaving the study early: any reason ‐ when compared with high dose (… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 2.33 [1.4, 3.86]
1 study · 70 participants
Moderate

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to higher global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.32 [1.06, 1.64]
2 studies · 172 participants
Moderate

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with high dose (greater than or equal to 10 mg/day) · patients with schizophrenia

LOW DOSE (greater than or equal to 2‐<4 mg/day) showed no clear difference in global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.07 [0.92, 1.25]
2 studies · 257 participants
Moderate

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia

LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to lower adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.44 [0.32, 0.6]
1 study · 124 participants
Moderate

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

LOW DOSE (greater than or equal to 2‐<4 mg/day) showed no clear difference in adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.81 [0.37, 1.75]
2 studies · 173 participants
Moderate

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus high dose ( greater than or equal to 10 mg) · patients with schizophrenia

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.45 [0.24, 0.84]
2 studies · 262 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: Any reasons ‐ when compared with ultra low dose (<2 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with ultra low… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.77 [0.55, 1.08]
2 studies · 461 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: Any reasons ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.78 [0.58, 1.06]
2 studies · 496 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ When compared with high dose… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.74 [0.54, 1]
1 study · 677 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.74 [0.34, 1.58]
1 study · 39 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Mental state: No clinically important improvement · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in mental state: No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).

4 findings from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.81 [0.64, 1.01]
1 study · 456 participants
Moderate
Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.94 [0.44, 2.03]
2 studies · 206 participants
Moderate
Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.06 [0.83, 1.36]
1 study · 457 participants
Moderate

Show 1 more finding

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.9 [0.74, 1.11]
1 study · 677 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Adverse effects: 6. Movement disorders ‐ specific symptoms ‐ dystonia ‐ versus low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) probably leads to higher adverse effects: 6. Movement disorders ‐ specific symptoms ‐… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 7.43 [1.07, 51.54]
1 study · 27 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Adverse effects: 6. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) probably leads to higher adverse effects: 6. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 2.28 [1.67, 3.11]
1 study · 124 participants
Moderate